NASDAQ · Biotechnology

Adagene Inc. (ADAG) Stock

$3.67 +1.66% NASDAQ: ADAG Healthcare

Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer.

Valuation

MetricValue
Price$3.67
Market Cap$138.17M
P/E Ratio-7.78
P/B Ratio3.94
P/S Ratio17.96
EPS (TTM)$-0.46
52-Week High$4.85
52-Week Low$1.30
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-48.20%
ROA-22.56%
ROCE-40.48%
Gross Margin92.43%
Operating Margin-279.39%
Net Margin-229.49%
Debt/Equity0.18
Current Ratio3.07

Annual Financials (USD)

Metric20212022202320242025
Revenue$10.0M$9.0M$18.0M$0$8.0M
Operating Profit$-72.0M$-84.0M$-24.0M$-36.0M$-21.0M
Net Profit$-73.0M$-80.0M$-19.0M$-33.0M$-18.0M
EPS$-2.29$-2.31$-0.54$-0.95$-0.46
Op Margin-711.2%-903.1%-131.0%-34835.4%-279.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$190.0M$152.0M$116.0M$89.0M$78.0M
Total Liabilities$33.0M$69.0M$45.0M$39.0M$43.0M
Cash$174.0M$144.0M$110.0M$85.0M$75.0M
Borrowings$7.0M$28.0M$22.0M$18.0M$6.0M

Latest News

Adagene (ADAG) Upgraded to Buy: Here's What You Should Know Zacks · Jun 5, 2026 Are Medical Stocks Lagging Adagene (ADAG) This Year? Zacks · Jun 2, 2026 Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer MarketBeat · May 19, 2026 Adagene to Participate in Two Upcoming Investor Conferences GlobeNewswire · May 12, 2026 Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer Insider Monkey · Apr 20, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-43.0M$-49.0M$-28.0M$-30.0M$-16.0M
Investing Cash Flow$-5.0M$-1.0M$0$1.0M$0
Financing Cash Flow$-4.0M$-4.0M$0$0$0
Net Cash Flow$99.0M$-31.0M$-34.0M$-25.0M$-11.0M
Free Cash Flow$-46.0M$-49.0M$-29.0M$-30.0M$-16.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.08
EV / EBITDA-3.34
FCF Yield-11.38%
Quick Ratio3.07
Interest Coverage-46.29
Return 1Y93.16%
Return 3Y151.37%
Return 5Y-80.29%

Ownership

Insiders Held21.61%
Institutions Held12.73%
Institutions Float Held16.24%
Institutional HolderSharesReport Date
HSG Holding Ltd1,343,3642026-03-31
Exome Asset Management LLC 736,8452026-03-31
Ameriprise Financial, Inc.607,9032026-03-31
Mill Creek Capital Advisors, LLC 199,6102026-03-31
Morgan Stanley66,1482026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACET $8.30 +1.22% -0.46 $77.59M 0.00%
CRVO $2.56 -3.76% -1.09 $23.70M 0.00%
FBIO $2.67 -3.61% 0.91 $88.69M 0.00%
GANX $1.73 -6.99% -2.70 $73.79M 0.00%
LITS $0.91 -2.31% -0.35 $30.88M 0.00%

About Adagene Inc.

Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.

Adagene Inc. is headquartered in CN.

Adagene Inc. (ADAG) stock trades at $3.67 with a market capitalization of $138.17M. The stock is valued at a price-to-earnings (P/E) ratio of -7.78, price-to-book of 3.94, price-to-sales of 17.96. Over the past 52 weeks the stock has ranged between $1.30 and $4.85, and currently trades 24.3% below its 52-week high.

On profitability, Adagene Inc. generates a return on equity (ROE) of -48.20%, return on capital employed of -40.48%, an operating margin of -279.39%, a net profit margin of -229.49%.

Official website: www.adagene.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides